GenSight Biologics SA (DE:G49N)
FRANKFURT:G49N
Holding DE:G49N?
Track your performance easily

GenSight Biologics SA (G49N) Income Statement

1 Followers

GenSight Biologics SA Income Statement

Last quarter (Q2 2022), GenSight Biologics SA's total revenue was €―, a decrease of ― from the same quarter last year. In Q2, GenSight Biologics SA's net income was €―. See GenSight Biologics SA’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 21Dec 20Dec 19Dec 18Dec 17
Total Revenue
-€ 5.28M€ 4.39M€ 700.00K€ 0.00€ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
-€ 33.40M€ 29.33M€ 31.00M€ 33.05M€ 23.99M
Operating Income
-€ -28.13M€ -24.93M€ -30.30M€ -33.05M€ -23.99M
Net Non Operating Interest Income Expense
-€ -2.17M€ -1.63M€ -407.00K€ -405.00K€ -78.00K
Other Income Expense
------
Pretax Income
-€ -28.61M€ -34.02M€ -30.86M€ -33.45M€ -24.11M
Tax Provision
-€ 2.00K€ 2.00K€ 4.00K€ 0.00€ 0.00
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-€ -28.62M€ -34.02M€ -30.87M€ -33.45M€ -24.11M
Basic EPS
-€ -0.63€ -0.97€ -1.08--
Diluted EPS
-€ -0.63€ -0.97€ -1.08--
Basic Average Shares
-€ 45.15M€ 35.13M€ 28.38M--
Diluted Average Shares
-€ 45.15M€ 35.13M€ 28.38M--
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
-€ 0.00€ 0.00€ 2.00K€ 3.00K€ 11.00K
Total Expenses
-€ 33.40M€ 29.33M€ 31.00M€ 33.05M€ 23.99M
Net Income From Continuing And Discontinued Operation
-€ -28.62M€ -34.02M€ -30.87M€ -33.45M€ -24.11M
Normalized Income
-€ -29.93M€ -26.66M€ -30.73M€ -33.45M€ -24.11M
Interest Expense
-€ 2.17M€ 1.72M€ 407.00K€ 408.00K€ 76.00K
EBIT
-€ -26.45M€ -32.30M€ -30.46M€ -33.05M€ -24.04M
EBITDA
-€ -25.52M€ -31.37M€ -29.47M€ -32.73M€ -23.81M
Currency in EUR

GenSight Biologics SA Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis